Mometasone furoate 0.1% w/w is a potent, synthetic, topical corticosteroid of the glucocorticoid class. It exerts anti-inflammatory, anti-pruritic, and vasoconstrictive actions. It is a medium-potency steroid (Class 3-4) and is a mainstay in the treatment of various steroid-responsive dermatoses in the Indian clinical setting due to its favorable efficacy-to-safety ratio and once-daily dosing.
Adult: Apply a thin film to the affected area once daily. The total duration should not exceed 4 weeks for most conditions without medical supervision.
Note: 1. Wash and dry hands and affected area. 2. Apply a thin film and rub gently until it disappears. 3. Do not bandage or cover the area unless directed by a physician (occlusion increases absorption). 4. Avoid contact with eyes, mouth, nose, and mucous membranes. 5. Wash hands after application unless hands are the treatment area.
Mometasone furoate acts by diffusing across cell membranes and binding with high affinity to cytoplasmic glucocorticoid receptors. The activated receptor complex translocates to the cell nucleus, where it modulates gene transcription. It induces the synthesis of anti-inflammatory proteins (lipocortin-1) and inhibits the synthesis of pro-inflammatory mediators.
Pregnancy: Pregnancy Category C (US FDA). Animal studies show teratogenicity. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Use the minimum effective dose for the shortest duration.
Driving: No known effects on the ability to drive or use machines.
| Other Topical Corticosteroids | Additive risk of local and systemic adverse effects. | Major |
| Topical Immunosuppressants (e.g., Tacrolimus, Pimecrolimus) | May be used in sequential therapy but concurrent use on same area may increase infection risk. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | May theoretically increase systemic levels of mometasone if significantly absorbed, increasing adverse effect risk. | Moderate |
Same composition (Mometasone (0.1% w/w)), different brands: